196 related articles for article (PubMed ID: 21460800)
1. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.
Hu Y; Bandla S; Godfrey TE; Tan D; Luketich JD; Pennathur A; Qiu X; Hicks DG; Peters JH; Zhou Z
Mod Pathol; 2011 Jul; 24(7):899-907. PubMed ID: 21460800
[TBL] [Abstract][Full Text] [Related]
2. Early HER2 dysregulation in gastric and oesophageal carcinogenesis.
Fassan M; Mastracci L; Grillo F; Zagonel V; Bruno S; Battaglia G; Pitto F; Nitti D; Celiento T; Zaninotto G; Fiocca R; Rugge M
Histopathology; 2012 Nov; 61(5):769-76. PubMed ID: 22882541
[TBL] [Abstract][Full Text] [Related]
3. Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation.
Langer R; Rauser S; Feith M; Nährig JM; Feuchtinger A; Friess H; Höfler H; Walch A
Mod Pathol; 2011 Jul; 24(7):908-16. PubMed ID: 21516080
[TBL] [Abstract][Full Text] [Related]
4. Cyclin E involved in early stage carcinogenesis of esophageal adenocarcinoma by SNP DNA microarray and immunohistochemical studies.
Zhou Z; Bandla S; Ye J; Xia Y; Que J; Luketich JD; Pennathur A; Peters JH; Tan D; Godfrey TE
BMC Gastroenterol; 2014 Apr; 14():78. PubMed ID: 24742107
[TBL] [Abstract][Full Text] [Related]
5. Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.
Thompson SK; Sullivan TR; Davies R; Ruszkiewicz AR
Ann Surg Oncol; 2011 Jul; 18(7):2010-7. PubMed ID: 21267790
[TBL] [Abstract][Full Text] [Related]
6. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma.
Yoon HH; Sukov WR; Shi Q; Sattler CA; Wiktor AE; Diasio RB; Wu TT; Jenkins RB; Sinicrope FA
Cancer; 2014 Feb; 120(3):415-24. PubMed ID: 24151090
[TBL] [Abstract][Full Text] [Related]
8. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas.
Yoon HH; Shi Q; Sukov WR; Wiktor AE; Khan M; Sattler CA; Grothey A; Wu TT; Diasio RB; Jenkins RB; Sinicrope FA
Clin Cancer Res; 2012 Jan; 18(2):546-54. PubMed ID: 22252257
[TBL] [Abstract][Full Text] [Related]
9. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus.
Reichelt U; Duesedau P; Tsourlakis MCh; Quaas A; Link BC; Schurr PG; Kaifi JT; Gros SJ; Yekebas EF; Marx A; Simon R; Izbicki JR; Sauter G
Mod Pathol; 2007 Jan; 20(1):120-9. PubMed ID: 17143264
[TBL] [Abstract][Full Text] [Related]
10. TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma.
Rossi E; Villanacci V; Bassotti G; Donato F; Festa A; Cengia G; Grisanti S; Cestari R
Histopathology; 2010 Jul; 57(1):81-9. PubMed ID: 20557373
[TBL] [Abstract][Full Text] [Related]
11. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
[TBL] [Abstract][Full Text] [Related]
12. Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma.
Zhan N; Dong WG; Tang YF; Wang ZS; Xiong CL
Med Oncol; 2012 Jun; 29(2):933-40. PubMed ID: 21318736
[TBL] [Abstract][Full Text] [Related]
13. The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis.
Fassan M; Pizzi M; Realdon S; Balistreri M; Guzzardo V; Zagonel V; Castoro C; Mastracci L; Farinati F; Nitti D; Zaninotto G; Rugge M
Hum Pathol; 2013 Sep; 44(9):1804-10. PubMed ID: 23618359
[TBL] [Abstract][Full Text] [Related]
14. Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma.
König AM; Reeh M; Dancau AM; Rathjens M; Gros S; Uzunoglu FG; Bockhorn M; Simon R; Sauter G; Marx A; Izbicki JR
Anticancer Res; 2013 Nov; 33(11):4975-82. PubMed ID: 24222138
[TBL] [Abstract][Full Text] [Related]
15. The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study.
Prins MJ; Ruurda JP; van Diest PJ; van Hillegersberg R; Ten Kate FJ
Ann Oncol; 2013 May; 24(5):1290-7. PubMed ID: 23334118
[TBL] [Abstract][Full Text] [Related]
16. Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
Walch A; Specht K; Bink K; Zitzelsberger H; Braselmann H; Bauer M; Aubele M; Stein H; Siewert JR; Höfler H; Werner M
Lab Invest; 2001 Jun; 81(6):791-801. PubMed ID: 11406641
[TBL] [Abstract][Full Text] [Related]
17. HER2/CHR 17 tissue microarray chromogenic in situ hybridization analysis in colon adenocarcinoma: multiple gene signals vs protein expression.
Fotiades PP; Tsiambas E; Lazaris AC; Saetta AA; Karameris A; Vilaras G; Patsouris E
J BUON; 2014; 19(1):109-14. PubMed ID: 24659651
[TBL] [Abstract][Full Text] [Related]
18. HER2 protein overexpression and gene amplification in upper urinary tract transitional cell carcinoma: systematic analysis applying tissue microarray technique.
Langner C; Gross C; Rehak P; Ratschek M; Rüschoff J; Zigeuner R
Urology; 2005 Jan; 65(1):176-80. PubMed ID: 15667899
[TBL] [Abstract][Full Text] [Related]
19. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma.
Tanaka T; Fujimura A; Ichimura K; Yanai H; Sato Y; Takata K; Okada H; Kawano S; Tanabe S; Yoshino T
World J Gastroenterol; 2012 Nov; 18(43):6263-8. PubMed ID: 23180947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
